Streetbeat News

CZMWY

Carl Zeiss Meditec A G

https://www.zeiss.de/meditec-ag/

CEO

Ludwin Monz

Industry

Surgical and Medical Instrument Manufacturing

Open

72.40

Mkt cap

6.1B

Volume

821

High

70.60

P/E Ratio

31.58

52-wk high

133.15

Low

69.17

Div yield

0.02

52-wk low

46.13

Carl Zeiss Meditec is a strong MedTech company with low debt and significant long-term potential. Despite macroeconomic challenges, it maintains robust fundamentals, high margins, and recurring sales. At sub-€60/share, it presents an attractive buy opportunity with expected recovery and upside by 2025-2028.

Portfolio Pulse from

December 04, 2024 | 8:15 am

Bernstein analyst Susannah Ludwig has initiated coverage on ophthalmology companies, recommending Alcon AG (NYSE:ALC) with an Outperform rating and a price target of $94.03, while giving Carl Zeiss Meditec AG (OTC:CZMWY) an Underperform rating with a price target of $82.31. Ludwig highlights the importance of innovation in the ophthalmology market, which is valued at $34 billion with mid-single digit growth rates. Alcon is noted for its significant R&D spending, which is 1.9 times higher than its next competitor, while Zeiss, though leading in digital, must maintain high R&D spending to stay competitive. Shares of Alcon and Carl Zeiss Meditec declined by 2.34% and 0.95%, respectively, at the time of publication.

Portfolio Pulse from Priya Nigam

January 23, 2024 | 5:47 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.